Work

Response: Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance (Endocrinol Metab2014;29:536-44, Min Jung Jung et al.)

Year: 2015
Type: article
Abstract: Thank you for your interest and comments on our article enti-tled “Expression of glucagon-like peptide-1 receptor in papil-lary thyroid carcinoma and its clinicopathologic significance,” which was published in Endocrinology and Metabolism [1]. We reported the expression of the glucagon-like peptide-1 receptor (GLP-1R) in papillary thyroid carcinoma (PTC) tis-sues based on immunohistochemical (IHC) staining. However, we could not find a meaningful relationship between clinical prognostic markers and GLP-1R expression in PTC, but the less multifocality of GLP-1R expression in PTC tissues. These findings were unexpected and interesting because previous studies reported that GLP-1R is not expressed in thyroid fol-licular cells and GLP-1 plays a possible role in cell prolifera-tion and apoptosis in pancreatic β-cells. IHC staining is well-established and used widely for identi-fying specific pathological processes, including protein ex-pression nevertheless, the pathologist’s interpretation is sub-jective. To convert the subjective perception of IHC marker expression into quantitative data, various semiquantitative scoring systems have been suggested. For example, in breast cancer, representative tumors were subjected to several IHC stains, including estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67. Pathologists use the quickscore, modi-fied H-score, immunoreactive score and Allred score [2,3] as generally accepted standard interpretation guidelines for IHC staining of ER and PR. In Allred score, pathologists score the proportions of ER-positive immunoreactive cells into six cate-gories (0, no cells are ER-positive; 1, ≤1%; 2, 1 % to 10%; 3,
Language: English
Field: Medicine
Open Access status: diamond
OpenAlex ID: W2165577634
FWCI:
Cites: 7
Cited by: 1
Related to: 10